Leerink Partnrs Issues Optimistic Estimate for KYTX Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Stock analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($4.20) per share for the year, up from their prior forecast of ($4.35). The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics' FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($4.66) EPS and FY2028 earnings at ($4.85) EPS.

Several other analysts have also weighed in on the stock. HC Wainwright dropped their price objective on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a "neutral" rating for the company in a report on Wednesday, November 20th. Wells Fargo & Company dropped their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, November 15th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $25.71.

Kyverna Therapeutics Trading Up 14.3 %

KYTX stock traded up $0.38 during trading on Monday, hitting $3.04. 463,469 shares of the stock traded hands, compared to its average volume of 413,178. Kyverna Therapeutics has a one year low of $2.64 and a one year high of $30.60. The company has a 50 day simple moving average of $3.69 and a 200 day simple moving average of $5.24.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.01. The firm had revenue of $0.01 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KYTX. The Manufacturers Life Insurance Company increased its stake in shares of Kyverna Therapeutics by 32.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company's stock valued at $283,000 after buying an additional 9,300 shares during the period. Creative Planning bought a new position in Kyverna Therapeutics in the third quarter valued at about $54,000. Novo Holdings A S increased its position in Kyverna Therapeutics by 5.7% in the third quarter. Novo Holdings A S now owns 1,850,000 shares of the company's stock worth $9,046,000 after purchasing an additional 100,000 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Kyverna Therapeutics by 33.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 166,635 shares of the company's stock worth $815,000 after purchasing an additional 41,558 shares during the last quarter. Finally, FMR LLC acquired a new position in Kyverna Therapeutics during the 3rd quarter valued at about $33,000. Institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.